CCM
REGN icon

Catapult Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Catapult Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-17,480
Closed -$3.93M – 293
2013
Q2 		$3.93M Buy
+17,480
New +$4.07M 1.64% 10

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's REGN Position: Q3 2013 in Review

Catapult Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2013, closing a stake of 17,480 shares — an estimated $3.93M sold.

Catapult Capital Management first reported a position in REGN in Q2 2013 and held it in 1 quarter. The position peaked at $3.93M in Q2 2013. 414 funds tracked by Wall St. Rank hold REGN as of Q3 2013.

  • Catapult Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Catapult Capital Management sold 17,480 Regeneron Pharmaceuticals shares in Q3 2013, an estimated $3.93M.
  • Catapult Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Catapult Capital Management's Regeneron Pharmaceuticals position peaked at $3.93M in Q2 2013.
  • 414 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2013.

Based on Catapult Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.